Hope on the Horizon: New Molecule Shows Promise Against Aggressive Breast Cancer
Researchers at Oregon Health & Science University (OHSU) have unveiled a promising new molecule, SU212, offering a potential breakthrough in the treatment of triple-negative breast cancer (TNBC). This aggressive form of the disease, accounting for approximately 15% of all breast cancer cases, currently lacks effective drug treatments, making this discovery a significant step forward.
Targeting the Engine of Cancer Growth: ENO1
The experimental molecule SU212 works by targeting and disrupting an enzyme called enolase 1 (ENO1). Cancer cells produce unusually high amounts of ENO1 to fuel their rapid growth and spread. In laboratory tests using a humanized mouse model mimicking human TNBC, SU212 caused ENO1 to break down, leading to reduced tumor growth and limited metastasis.
“It’s an important step forward to treat triple-negative breast cancer,” said Dr. Sanjay V. Malhotra, co-director of the Center for Experimental Therapeutics at the OHSU Knight Cancer Institute. “Triple-negative breast cancer is an aggressive form of cancer and there are no effective drugs available right now.”
Beyond Breast Cancer: A Potential Multi-Cancer Solution?
The potential of SU212 extends beyond TNBC. Researchers believe that targeting ENO1 could be beneficial in treating other cancers where this enzyme plays a crucial role, including glioma, pancreatic cancer, and thyroid carcinoma. This broad applicability highlights the importance of understanding fundamental cancer mechanisms to develop broadly effective therapies.
Dr. Malhotra noted the mechanism may be particularly relevant for patients with metabolic disorders like diabetes, which leads to high blood sugar levels.
The Road to Clinical Trials and Beyond
While the preclinical results are encouraging, SU212 is not yet available for patient treatment. The next crucial step involves advancing the molecule toward human clinical trials. This process requires substantial resources and approval from the Food and Drug Administration (FDA).
The research, published in Cell Reports Medicine, was supported by funding from the National Institutes of Health, the Department of Defense, and OHSU. Dr. Malhotra’s work builds on research initially conducted at the National Cancer Institute and continued at Stanford University.
The Future of Cancer Metabolism Research
The development of SU212 exemplifies a growing trend in cancer research: targeting cancer metabolism. Cancer cells have altered metabolic pathways compared to normal cells, making them vulnerable to interventions that disrupt these processes. This approach offers the potential for more selective and effective cancer treatments with fewer side effects.
OHSU’s Center for Experimental Therapeutics, led in part by Dr. Malhotra, is dedicated to translating laboratory discoveries into clinical applications for the benefit of patients.
Frequently Asked Questions
What is triple-negative breast cancer?
TNBC is an aggressive form of breast cancer that lacks the typical receptors found in other types of breast cancer, making it harder to treat with standard therapies.
What does SU212 do?
SU212 targets and breaks down the ENO1 enzyme, which cancer cells use to grow and spread.
When will SU212 be available for patients?
SU212 is still in the preclinical stage and requires clinical trials before it can be approved for patient use.
Could SU212 treat other cancers?
Researchers believe SU212 may be effective against other cancers that rely on the ENO1 enzyme, such as glioma, pancreatic cancer, and thyroid carcinoma.
What is enolase 1 (ENO1)?
ENO1 is an enzyme that helps cells convert glucose into energy. Cancer cells produce unusually high amounts of ENO1 to fuel their rapid growth.
Did you recognize? Targeting cancer metabolism is a rapidly growing area of research, offering the potential for new and more effective cancer treatments.
Pro Tip: Staying informed about the latest cancer research can empower you to have informed conversations with your healthcare provider.
Learn more about ongoing cancer research at OHSU’s Knight Cancer Institute.
Have questions about breast cancer or cancer research? Share your thoughts in the comments below!
Related reading